News

Keep up to date with us.

Learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials

Join us virtually on December 1 at 10AMPT/12PM CT/1PM ET at the 5th Annual NASH Summit 2021 to learn about The Power of 3D Liver Ultrasound for NASH Clinical Trials, featuring Dr. Stephen Harrison, Medical Director, Pinnacle Clinical Research & President, Summit Clinical Research; and George Aliphtiras, CEO, Sonic Incytes Medical Corp.

Key takeaways include:

  • Understand the technology behind Velacur, the first handheld 3D liver health assessment solution
  • Learn about the power of 3D liver ultrasound in quantifying liver disease (elasticity and attenuation) in comparison to MR elastography and MRI-PDFF
  • Discover the ways in which Velacur can be a cost-effective tool for liver assessment in clinical trials of promising NASH drugs

Developed by Sonic Incytes Medical Corp., VelacurTM is a breakthrough, point of care ultrasound solution that is redefining the standard of care for chronic liver disease. With diagnostic accuracy comparable to MRI, VelacurTM combines the principles of MRI with handheld ultrasound to quantify liver disease with greater accuracy and reliability than the current standard of care.

Visit https://nash-summit.com/program/full-event-guide/ for more info.